Immune Response News and Research

RSS

BCG vaccination appears to trigger cross-reactive SARS-CoV-2-specific T cell response

Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.

24 Nov 2020

Mild COVID-19 disease may trigger long-term immunity

Researchers in the United States have conducted a study showing that individuals who have recovered from mild coronavirus disease 2019 (COVID-19) developed sustained protective immune memory against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Nov 2020

Sex steroids may play a protective role in COVID-19, shows study

A new paper from a UIC researcher shows evidence that suggests sex steroids may play a role in protecting against COVID-19 symptoms.

24 Nov 2020

The role of micro-RNA in SARS-CoV-2 infection and COVID-19

A team of researchers based in Iran have explored the role of micro-RNA in COVID-19. Their study titled, “The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection,” was published in the latest issue of the journal International Immunopharmacology.

24 Nov 2020

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

A new study released on the medRxiv* preprint server indicates that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic – is developing multiple mutations that affect neutralization by antibodies.

24 Nov 2020

Biosensor assay SARS-CoV-2 antibody test may predict COVID-19 severity in patients

Researchers in New York, USA, have found an association of mortality with an early humoral response to SARS-CoV-2 infection within the first few days after onset of symptoms (DAOS), using a highly sensitive and automated testing-on-a-probe (TOP) biosensor assays for SARS-CoV-2.

24 Nov 2020

COVID-19: HLA class I genotypes and mortality

The study, published on the preprint server medRxiv, explores the ability of HLA class I molecules to mediate the outcome in COVID-19 patients.

24 Nov 2020

Reprogramming T cells into highly active 'super immune cells' can improve immunotherapy benefits

Immune-system T cells have been reprogrammed into regenerative stem cell-like memory (TSCM) cells that are long-lived, highly active "super immune cells" with strong antitumor activity, according to new research from Georgetown Lombardi Comprehensive Cancer Center.

23 Nov 2020

SARS-CoV-2's spike protein mutations have slowed, study finds

A team of researchers at the School of Information Sciences in Illinois, USA, has revealed the rate of mutation in the 29 proteins that make up the SARS-CoV-2 microbe.

23 Nov 2020

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

A thought-provoking new study reports that the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies elicited by natural infection may not be able to neutralize emerging strains that display deletion mutations in their genomic RNA.

23 Nov 2020

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

A team of researchers from the USA and China have engineered a receptor-binding domain (RBD) that they claim improves the immunogenicity of multivalent SARS-CoV-2 vaccines. Their study, which was released on the bioRxiv* in November 2020, may help advance even more efficacious SARS-CoV-2 vaccine candidates in the future.

23 Nov 2020

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

A startling new case study of Chicago, led by a team of researchers at Northwestern University in Illinois, USA, suggests a 16-fold higher incidence of SARS-CoV-2 infection than previously thought. This is judging from seroprevalence (antibody presence blood testing) figures, rather than the number of RT-PCR-positives reported there (via swab sample testing of symptomatic patients).

23 Nov 2020

Inflammatory factors that aggravate COVID-19 may come from adipose tissue

There is growing evidence that adipose tissue plays a key role in the aggravation of COVID-19. One of the theories under investigation is that fat cells (adipocytes) act as a reservoir for SARS-CoV-2 and increase viral load in obese or overweight individuals.

20 Nov 2020

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

A genetic modification in the 'coat' of a brain infection-causing virus may allow it to escape antibodies, according to Penn State College of Medicine researchers.

20 Nov 2020

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.

19 Nov 2020

New combination treatment for recurrent ovarian cancer shows positive outcomes

A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.

19 Nov 2020

New findings support current and planned clinical trials of Janssen SARS-CoV-2 vaccine

Researchers from the United States and The Netherlands have conducted a pre-clinical study supporting the initiation of a Phase 3 trial to test a two-dose regimen of the Janssen Ad26.COV2.S vaccine candidate among adult and elderly individuals.

19 Nov 2020

Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study

In a recent study, a team of researchers at Northwestern University, USA, had found that nearly 20 percent seroprevalence in the United States metropolitan site, Chicago, over the summer, during a period when lockdown restrictions were eased. They found that three-quarters of seropositive individuals retained detectable antibodies for at least 120 days or four months.

19 Nov 2020

UK’s COVID-19 vaccine shows similar safety and immunogenicity results in healthy older adults

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 years.

19 Nov 2020

Scientists discover potential strategy to prevent inflammation in COVID-19 patients

The COVID-19 pandemic continues to cause significant illness and death while treatment options remain limited. St. Jude Children's Research Hospital scientists have discovered a potential strategy to prevent life-threatening inflammation, lung damage and organ failure in patients with COVID-19. The research appeared online in the journal Cell.

19 Nov 2020

Immune Response News and Research

BCG vaccination appears to trigger cross-reactive SARS-CoV-2-specific T cell response

Mild COVID-19 disease may trigger long-term immunity

Sex steroids may play a protective role in COVID-19, shows study

The role of micro-RNA in SARS-CoV-2 infection and COVID-19

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

Biosensor assay SARS-CoV-2 antibody test may predict COVID-19 severity in patients

COVID-19: HLA class I genotypes and mortality

Reprogramming T cells into highly active 'super immune cells' can improve immunotherapy benefits

SARS-CoV-2's spike protein mutations have slowed, study finds

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

Inflammatory factors that aggravate COVID-19 may come from adipose tissue

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

New combination treatment for recurrent ovarian cancer shows positive outcomes

New findings support current and planned clinical trials of Janssen SARS-CoV-2 vaccine

Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study

UK’s COVID-19 vaccine shows similar safety and immunogenicity results in healthy older adults

Scientists discover potential strategy to prevent inflammation in COVID-19 patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News